NCT04746313

Prevalence of Hyperprolactinemia in Systemic Scleroderma

Assessment of the Prevalence of Hyperprolactinemia in Systemic Scleroderma

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 71 (actual)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Systemic sclerosis is an autoimmune and inflammatory disease characterized primarily by fibrosis and vascular involvement. We know that the immune system is disrupted in systemic sclerosis, but there are probably other mechanisms to explain the disease, including deregulation of certain proteins such as prolactin

Conditions

• Sclerosis, Systemic
• Scleroderma
• Hyperprolactinemia

Interventions

Type	Name	Description
BIOLOGICAL	blood test	* to analysis prolactin in healthy subjects and scleroderma patients * then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin

Timeline

• Start date: 2021-03-01
• Primary completion: 2021-05-12
• Completion: 2021-05-12
• First posted: 2021-02-09
• Last updated: 2025-12-23

Locations

1 site across 1 country: France